2022
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2022, 66: 23-32. PMID: 36255460, DOI: 10.1007/s00125-022-05815-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSGLT2 inhibitorsDrug categoriesSodium-glucose cotransporter 2 inhibitorsCardio-renal benefitsNormal blood glucose concentrationsCotransporter 2 inhibitorsClasses of medicationsAnti-inflammatory effectsSerious adverse effectsType 1 diabetesBlood glucose levelsBlood glucose concentrationKidney outcomesRare complicationBlood pressureSGLT2 inhibitionGlucose levelsKetone levelsBody weightType 2Ketone bodiesAdverse effectsGlucose concentrationInhibitorsEdged sword
2021
Continuous Glucose Monitoring for the Internist
Lee GS, Lupsa BC. Continuous Glucose Monitoring for the Internist. Medical Clinics Of North America 2021, 105: 967-982. PMID: 34688421, DOI: 10.1016/j.mcna.2021.06.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsContinuous glucose monitoringContinuous glucose monitoring systemDiabetes mellitusGlucose monitoring systemGlucose monitoringGlycemic patternsType 2 diabetes mellitusType 1 diabetes mellitusTreatment regimenDiabetes careGlucose readingsHemoglobin AGlucose dataMellitusPatientsInterstitial fluidConvenient wearable devices
2019
Personalized Management of Type 2 Diabetes
Peter PR, Lupsa BC. Personalized Management of Type 2 Diabetes. Current Diabetes Reports 2019, 19: 115. PMID: 31686226, DOI: 10.1007/s11892-019-1244-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesManagement of patientsUnique patient characteristicsSpecific patient subpopulationsClass of agentsGlycemic targetsTreatment landscapeMedical therapyPatient characteristicsPharmacotherapeutic optionsPatient subpopulationsIndividualized carePersonalized managementClinical practiceType 2ReviewOur goalRecent FindingsWePatientsDiabetesTherapyManagementPhysiciansCare
2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018, 61: 2118-2125. PMID: 30132031, DOI: 10.1007/s00125-018-4663-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsWeight LossConceptsSGLT2 inhibitorsSodium-glucose cotransporter 2 inhibitorsPostprandial blood glucose levelsEuglycaemic diabetic ketoacidosisGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetic kidney diseaseGenitourinary tract infectionsLower extremity amputationHigh-risk individualsBlood glucose levelsPlasma glucose concentrationCardiovascular outcomesDiabetic ketoacidosisUrinary frequencyTract infectionsOptimal prescribingNew drug categoryKidney diseaseGlucose reabsorptionGlucose levelsHigh riskDrug categoriesBody weightBone fracturesDiabetes medications and cardiovascular disease
Lupsa BC, Inzucchi SE. Diabetes medications and cardiovascular disease. Current Opinion In Endocrinology Diabetes And Obesity 2018, 25: 87-93. PMID: 29369916, DOI: 10.1097/med.0000000000000400.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitus patientsPeptide-1 receptor agonistsGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetes mellitus patientsType 2 diabetesCause of mortalityCardiovascular complicationsCardiovascular outcomesDiabetes medicationsMicrovascular complicationsCardiovascular effectsMellitus patientsReceptor agonistDrug categoriesIntensive controlDiseaseComplicationsMedicationsClear benefitRecent studiesSignificant improvement
2017
A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors
Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors. Journal Of Gastrointestinal Surgery 2017, 21: 1335-1341. PMID: 28510792, DOI: 10.1007/s11605-017-3428-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsSystematic reviewRare pancreatic neuroendocrine tumorYale-New Haven HospitalMajority of patientsMedian tumor diameterLower insulin levelsBiomedical databases PubMedNew Haven HospitalSymptomatic hypoglycemiaMost patientsFemale predominanceTumor diameterClinicopathologic featuresInsulin levelsUncommon diseaseMean ageOvid MEDLINEHormonal levelsDatabases PubMedPatientsProinsulinomaHormone productionTumors
2015
Bone Health and Osteoporosis
Lupsa BC, Insogna K. Bone Health and Osteoporosis. Endocrinology And Metabolism Clinics Of North America 2015, 44: 517-530. PMID: 26316240, DOI: 10.1016/j.ecl.2015.05.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone healthBone lossLow bone massAdditional risk factorsDual-energy X-ray absorptiometry measurementsLow-energy fracturesBone mineral densityMicroarchitectural deteriorationEstrogen levelsSmoking cessationRisk factorsMineral densityPharmacologic agentsBone massHigh riskOlder womenWomen's ageBone strengthAbsorptiometry measurementsOsteoporosisGold standardBone tissueRiskHealthFracturesPrecipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. Diabetes Care 2015, 38: e55-e57. PMID: 25805871, PMCID: PMC4370325, DOI: 10.2337/dc14-2349.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2010
Cardiomyopathy in Congenital and Acquired Generalized Lipodystrophy
Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in Congenital and Acquired Generalized Lipodystrophy. Medicine 2010, 89: 245-250. PMID: 20616664, PMCID: PMC3090142, DOI: 10.1097/md.0b013e3181e9442f.Peer-Reviewed Original ResearchConceptsCohort of patientsGeneralized lipodystrophyCardiac findingsInsulin resistanceHypertrophic cardiomyopathyAcquired Generalized LipodystrophyLower leptin levelsExtreme insulin resistanceDiabetes mellitusLeptin therapyLeptin levelsSevere dyslipidemiaCardiac statusFrequent findingClinical trialsRare disorderPatientsAdipose tissueCardiomyopathyLipodystrophyCongenitalSeipin mutationsUnderlying mechanismPhenotypic featuresCohortTreatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies
Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P. Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: 3641-3647. PMID: 20484479, PMCID: PMC2913034, DOI: 10.1210/jc.2010-0167.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAutoantibodiesBlood GlucoseCyclophosphamideDrug Therapy, CombinationFemaleHumansHyperandrogenismHyperglycemiaImmunosuppressive AgentsInsulin ResistanceMaleMiddle AgedReceptor, InsulinRituximabTreatment OutcomeConceptsType B insulin resistanceInsulin resistanceAmelioration of hyperglycemiaPathogenic autoantibody productionSerious adverse eventsRare autoimmune disorderInitiation of treatmentForm of immunosuppressionInsulin receptor autoantibodiesSevere acanthosis nigricansAdverse eventsInsulin therapyMedication regimenPulse corticosteroidsInsulin doseReceptor autoantibodiesAutoantibody productionAcanthosis nigricansAutoimmune disordersGlycated hemoglobinStandardized treatmentTreatment protocolEndocrine parametersPatientsSteroids results
2009
Efficacy of leptin therapy in the different forms of human lipodystrophy
Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2009, 53: 27. PMID: 19727665, DOI: 10.1007/s00125-009-1502-9.Peer-Reviewed Original ResearchConceptsForms of lipodystrophyLipodystrophy patientsLeptin therapyLeptin replacementSerum triacylglycerolOpen-label prospective studySevere insulin resistanceNational InstituteGlycaemic controlHDL cholesterolLDL cholesterolTotal cholesterolMetabolic abnormalitiesKidney diseaseProspective studyInsulin resistanceRare disorderSustained improvementPatientsAdipose tissueLipodystrophyHuman lipodystrophyPPARγ geneTherapyDyslipidaemiaAutoimmune Forms of Hypoglycemia
Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune Forms of Hypoglycemia. Medicine 2009, 88: 141-153. PMID: 19440117, DOI: 10.1097/md.0b013e3181a5b42e.Peer-Reviewed Original ResearchConceptsInsulin autoimmune syndromeType B insulin resistanceAnti-insulin receptor antibodiesAutoimmune syndromeAutoimmune formInsulin resistanceReceptor antibodiesPancreatic surgical proceduresCause of hypoglycemiaNon-Asian patientsAnti-insulin antibodiesNon-Asian populationsLaboratory featuresClinical courseWhite patientsHypoglycemic patientsRare causeInsulin levelsHyperinsulinemic hypoglycemiaSurgical proceduresCorrect diagnosisHypoglycemiaPatientsSyndromeElevated levels